Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Quality of life as a prognostic marker in pulmonary arterial hypertension (2014)

  • Authors:
  • USP affiliated authors: SOUZA, ROGÉRIO DE - FM
  • USP Schools: FM
  • DOI: 10.1186/s12955-014-0130-3
  • Subjects: HIPERTENSÃO PULMONAR (TERAPIA); QUALIDADE DE VIDA; PROGNÓSTICO
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1186/s12955-014-0130-3 (Fonte: oaDOI API)
    • Este periódico é de acesso aberto
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: gold
    • Licença: cc-by

    Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM2520780-10BCSEP 473 2014
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      FERNANDES, Caio; MARTINS, Barbara; JARDIM, Carlos; et al. Quality of life as a prognostic marker in pulmonary arterial hypertension. Health and Quality of Life Outcomes, London, v. 12, p. 130, 2014. Disponível em: < doi: 10.1186/s12955-014-0130-3. > DOI: 10.1186/s12955-014-0130-3.
    • APA

      Fernandes, C., Martins, B., Jardim, C., Ciconelli, R., Morinaga, L., Breda, A. P., et al. (2014). Quality of life as a prognostic marker in pulmonary arterial hypertension. Health and Quality of Life Outcomes, 12, 130. doi:10.1186/s12955-014-0130-3
    • NLM

      Fernandes C, Martins B, Jardim C, Ciconelli R, Morinaga L, Breda AP, Hoette S, Souza R. Quality of life as a prognostic marker in pulmonary arterial hypertension [Internet]. Health and Quality of Life Outcomes. 2014 ;12 130.Available from: doi: 10.1186/s12955-014-0130-3.
    • Vancouver

      Fernandes C, Martins B, Jardim C, Ciconelli R, Morinaga L, Breda AP, Hoette S, Souza R. Quality of life as a prognostic marker in pulmonary arterial hypertension [Internet]. Health and Quality of Life Outcomes. 2014 ;12 130.Available from: doi: 10.1186/s12955-014-0130-3.

    Referências citadas na obra
    Souza R, Jardim C, Humbert M: Idiopathic pulmonary arterial hypertension. Semin Respir Crit Care Med 2013, 34: 560–567. 10.1055/s-0033-1355439
    McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M: Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013, 62: D51-D59. 10.1016/j.jacc.2013.10.023
    Hoette S, Jardim C, Souza R: Diagnosis and treatment of pulmonary hypertension: an update. J Bras Pneumol 2010, 36: 795–811. 10.1590/S1806-37132010000600018
    Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165: 800–804. 10.1164/ajrccm.165.6.2106079
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346: 896–903. 10.1056/NEJMoa012212
    Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353: 2148–2157. 10.1056/NEJMoa050010
    Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, Szturmowicz M: Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006, 129: 1313–1321. 10.1378/chest.129.5.1313
    Souza R, Jardim C, Carvalho C, Rubenfeld G: The role of NT-proBNP as a prognostic marker in pulmonary hypertension. Chest 2006, 130: 1627. author reply 1627–8 10.1378/chest.130.5.1627
    Souza R, Jardim C, Julio Cesar Fernandes C, Silveira Lapa M, Rabelo R, Humbert M: NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med 2007, 101: 69–75. 10.1016/j.rmed.2006.04.014
    Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A: A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009, 30: 394–403. 10.1093/eurheartj/ehp022
    Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK: Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004, 126: 1452–1459. 10.1378/chest.126.5.1452
    Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC: Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes 2013, 11: 161. 10.1186/1477-7525-11-161
    McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006, 15: 103–115. 10.1007/s11136-005-3513-4
    McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD, The MOS: 36-item Short-Form Health Survey (SF-36): III: tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994, 32: 40–66. 10.1097/00005650-199401000-00004
    Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, Westlake L: Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992, 305: 160–164. 10.1136/bmj.305.6846.160
    Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ: Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007, 26: 181–187. 10.1016/j.healun.2006.11.009
    Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M: Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin 2009, 25: 2479–2485. 10.1185/03007990903210066
    Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB: Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149: 521–530. 10.7326/0003-4819-149-8-200810210-00004
    Souza R, Jardim C, Martins B, Cortopassi F, Yaksic M, Rabelo R, Bogossian H: Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin 2005, 21: 907–911. 10.1185/030079905X46232
    Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013, 62: D34-D41. 10.1016/j.jacc.2013.10.029
    ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166: 111–117.
    Costa EL, Jardim C, Bogossian HB, Amato MB, Carvalho CR, Souza R: Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria. Vascul Pharmacol 2005, 43: 143–147. 10.1016/j.vph.2005.05.004
    Ciconelli R, Ferraz MB, Santos W, Quaresma M: Tradução para a Língua Portuguesa e validação do questionário genérico da avaliação de qualidade de vida SF-36 (Brasil SF-36). Rev Bras Reumatol 1999, 39: 8.
    Fernandes CJ, Jardim CV, Hovnanian A, Hoette S, Morinaga LK, Souza R: Schistosomiasis and pulmonary hypertension. Expert Rev Respir Med 2011, 5: 675–681. 10.1586/ers.11.58
    Hovnanian A, Hoette S, Fernandes CJ, Jardim C, Souza R: Schistosomiasis associated pulmonary hypertension. Int J Clin Pract Suppl 2010, 25–28.
    Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD: An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012, 142: 448–456. 10.1378/chest.11-1460
    Souza R, Martins BC, Jardim C, Cortopassi F, Fernandes CJ, Pulido T, Sandoval J: Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension. Int J Clin Pract 2007, 61: 153–156. 10.1111/j.1742-1241.2006.01222.x
    Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117: 3010–3019. 10.1161/CIRCULATIONAHA.107.742510
    Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S: Effect of pulmonary arterial hypertension specific therapies on health-related quality of life: a systematic review. Chest 2014.
    Roman A, Barbera JA, Castillo MJ, Munoz R, Escribano P: Health-related quality of life in a national cohort of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Arch Bronconeumol 2013, 49: 181–188. 10.1016/j.arbres.2012.12.007
    Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002, 40: 780–788. 10.1016/S0735-1097(02)02012-0
    Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J: Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005, 26: 858–863. 10.1183/09031936.05.00075305
    Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD: Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012, 126: 349–356. 10.1161/CIRCULATIONAHA.112.105890
    Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP: Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009, 135: 137–142. 10.1378/chest.07-0275
    Cima K, Twiss J, Speich R, McKenna SP, Grunig E, Kahler CM, Ehlken N, Treder U, Crawford SR, Huber LC, Ulrich S: The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). Health Qual Life Outcomes 2012, 10: 110. 10.1186/1477-7525-10-110
    Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, Twiss J, McKenna SP: Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J 2008, 15: 77–83.
    Selimovic N, Rundqvist B, Kjork E, Viriden J, Twiss J, McKenna SP: Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden. Scand J Public Health 2012, 40: 777–783. 10.1177/1403494812464445
    Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP: United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008, 27: 124–130. 10.1016/j.healun.2007.10.004
    Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E: Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology 2011, 16: 1235–1240. 10.1111/j.1440-1843.2011.02030.x
    McCabe C, Bennett M, Doughty N, MacKenzie Ross R, Sharples L, Pepke-Zaba J: Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest 2013, 144: 522–530. 10.1378/chest.12-2443
    Dos Santos Fernandes CJ, Jardim CV, Hovnanian A, Hoette S, Dias BA, Souza S, Humbert M, Souza R: Survival in schistosomiasis-associated pulmonary arterial hypertension. J Am Coll Cardiol 2010, 56: 715–720. 10.1016/j.jacc.2010.03.065
    Fernandes CJ, Dias BA, Jardim CV, Hovnanian A, Hoette S, Morinaga LK, Souza S, Suesada M, Breda AP, Souza R: The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension. Chest 2012, 141: 923–928. 10.1378/chest.11-0483
    Lapa M, Dias B, Jardim C, Fernandes CJ, Dourado PM, Figueiredo M, Farias A, Tsutsui J, Terra-Filho M, Humbert M, Souza R: Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009, 119: 1518–1523. 10.1161/CIRCULATIONAHA.108.803221